Reig Jofre is a Spanish pharmaceutical company founded in 1929 and focused on the research, development, manufacture and marketing of pharmaceutical products and nutritional supplements (80% of sales), as well as on specialised contract development and manufacturing (20% of sales).
Reig Jofre has 850 employees, 4 development centers and 3 manufacturing sites in Europe, direct sales in 6 countries in Europe and over 130 commercial partners in 58 countries worldwide. The company reached sales of € 157 M in 2015 and is #5 Spanish pharmaceutical company by turnover listed on the Spanish stock exchange (ticker RJF).
Reig Jofre’s three product categories are: i) technological-specialisation products (i.e. beta-lactam antibiotics, injectable and freeze-dried products); ii) therapeutic-specialisation products in the areas of dermatology, respiratory/ENT and gynaecology; and iii) food supplements and consumer healthcare products.
High technology standards and a sound track record in the above technological specialisation have turned Reig Jofre as the chosen partner of many companies worldwide for their developments and manufacturing needs in these fields.
Reig Jofre focuses its R+D strategy on new indications of existing molecules and new routes of administration and dosage of already-known active principles, as well as on the development of injectable, freeze-dried and generic beta-lactam antibiotics. It also has a special interest in the identification of collaborative projects with start-ups and biotech research centres.
Reig Jofre offers an extensive list of branded products and in-house developed generic dossiers for international markets, ensuring excellent- and recognized quality in all processes, personalized service and a reliable supply with long-term competitive prices.
Reig Jofre is also interested in product in-licensing in the areas of hospital, paediatrics and dermatology, where the company has a strong presence in the market.